Role of Glucosamine Sulphate Supplements on Intra Ocular Pressure Given in Osteoarthritis Treatment – A Case Series

Authors

Dr N. Suhasini¹, Dr M. Harini²*, Dr T. Rajasekhar³

¹M.S (Ophthalmology) FIGS, Asst. Prof. Ophthal GIMSR
²M.S (E.N.T) Asst. Prof. ENT-GIMSR
³DNB (Orthopaedics) Senior Resident Ortho-GIMSR

*Corresponding Author

Dr M. Harini

Flat No.302, Prathima Paradise Apartments, Opp. Gokul Park, Visakhapatnam-530002, India

Abstract

Aim: To analyze role of Glucosamine sulphate supplements given for treatment of Osteoarthritis on intraocular pressure.

Materials & Methods: A case series of 100 patients who were diagnosed to have Osteoarthritis were selected and started on Glucosamine sulphate supplements in whom IOP was measured and analyzed for 1 year (From March 2017-March 2018) in GIMSR

Results: Out of 111 patients selected for study, 11 patients were excluded as they were having high IOP, glaucomatous changes in fundus, corneal irregularities and postoperative cases

- Out of 100 patients 78 were females and 22 were males
- Most common age group being 40 to 60 years in both males and females
- IOP changes were more common in females than males
- IOP rise of 2mm Hg was identified in both eyes after a period of 1 year in considerable no of patients

Conclusions: Out of total number of 20,000 patients attended Orthopaedics department from March 2017 to March 2018 in GIMSR, 5000 patients complained of knee problem. Among them 100 patients were selected for the study. Patients with previous history of glaucoma, previous surgeries, fundus changes, not willing for regular follow up and corneal abnormalities were excluded from the study. Measurement of IOP was done in all 100 patients before starting of Glucosamine sulphate and patients were instructed to come for regular follow-ups 5 times at 3 months interval.

- In our study major proportion of patients were females constituting 78% compared to males who were only 22%
- Commonest age group affected both in males and females was 40-60 years
- Normal range of 10 to 20 mm Hg IOP was seen in almost 90% of patients
- After administration of Glucosamine for a period of 3 months not much IOP change is noticed
- After 6 months 34% of patients have shown 2 mm Hg increase in IOP in both eyes but were within normal range
- Thus Glucosamine sulphate can be used in Osteoarthritis with regular monitoring of IOP and considered to be relatively safe.

Keywords: Glaucoma, intraocular pressure, Osteoarthritis.
Introduction
An amino monosaccharide Glucosamine is an essential constituent of cartilage. Glucosamine sulphate supplements widely used for Osteoarthritis treatment appear to increase IOP, researchers say. Though evidence is lacking that it can improve symptoms of Osteoarthritis, radiographic studies have shown that it slows joint space width loss and hence appears to be safe & popular as a treatment. However Glucosamine is also abundant in corneal stroma and plays a role in morphology and function of the trabecular meshwork.

One small retrospective study showed an association between Glucosamine supplement usage and IOP. Glycosaminoglycans constitute ground substance for outermost part of the trabecular meshwork. Long, flexible chains of GAG interact with each other to form a system of entangled polyanionic macromolecules which act like a gel and contribute to outflow resistance. Accumulated GAG in ground substance of trabecular meshwork outflow pathways and increased constriction of the trabecular spaces could explain rise in IOP seen with even short courses of steroid treatment.

In this study our aim was to study role of Glucosamine supplements in Osteoarthritis patients on IOP among patients attending Orthopaedics department in GIMSR. This is a prospective study conducted over a period of 1 year from March 2017 to March 2018 in GIMSR.

Aims & Objectives
To find out role of Glucosamine sulphate supplements given in Osteoarthritis patients on IOP attending outpatient Orthopaedics and Ophthalmology departments in GIMSR.

Materials & Methods
This is a prospective study conducted over a period of one year from March 2017 to March 2018 in GIMSR.

Out of all patients attending Orthopedics department with osteoarthritis, 111 patients were selected and started on Glucosamine sulphate 750 mg thrice a day and were sent to Ophthalmology department for evaluation before starting treatment. The patients were asked for follow up in 5 consecutive visits. Patients already diagnosed with more IOP and fundus changes were excluded and 100 patients were selected finally for study.

Inclusion Criteria
- Patients of all age groups on Glucosamine supplements.
- Patients giving consent for the study
- Patients willing to come for regular follow up.

Exclusion Criteria
- Patients not giving consent for study
- Patients already having raised IOP.
- Patients not coming for regular follow up.
- Patients with fundus changes.
- Post operative patients
- Patients with corneal irregularities and dystrophies.

Observations
From March 2017 to March 2018 total number of patients attended Orthopaedics department were 20000, out of which 5000 patients complained of knee problem. All patients were sent to Ophthalmology department. Out of them 100 patients were finally selected and started on Glucosamine sulphate drug.
Out of 100 patients selected for the study 78 were females (78%) and 22 were males (22%)

**Table 1:** shows sex distribution in the study revealing females were more effected than males

![Sex Distribution Chart]

**Table 2:** shows that major age group which was effected in both sexes was 40-60 years constituting 43% in females and 14% in males

<table>
<thead>
<tr>
<th>Age group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-40 yrs</td>
<td>15</td>
<td>1</td>
<td>16</td>
<td>16%</td>
</tr>
<tr>
<td>40-60 yrs</td>
<td>43</td>
<td>14</td>
<td>57</td>
<td>57%</td>
</tr>
<tr>
<td>&gt;60 yrs</td>
<td>20</td>
<td>7</td>
<td>27</td>
<td>27%</td>
</tr>
<tr>
<td>Total</td>
<td>78</td>
<td>22</td>
<td>100</td>
<td>100%</td>
</tr>
</tbody>
</table>

**Table 3:** shows IOP recorded in both eyes before administration of drug (Normal IOP measurement is around 10 to 20 mm Hg)

<table>
<thead>
<tr>
<th>IOP</th>
<th>Right eye</th>
<th>Left eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10mm Hg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10-15mm Hg</td>
<td>80</td>
<td>87</td>
</tr>
<tr>
<td>15-20mm Hg</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>20-25mm Hg</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>25-30mm Hg</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>&gt;30mm Hg</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

**Table 4:** Results showing rise in IOP after usage of drug for a period of 1 year.
(There was definitely rise but within normal range of 10 to 20 mm Hg)

<table>
<thead>
<tr>
<th>IOP</th>
<th>Right eye</th>
<th>Left eye</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10mm Hg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10-15mm Hg</td>
<td>50</td>
<td>70</td>
</tr>
<tr>
<td>15-20mm Hg</td>
<td>46</td>
<td>26</td>
</tr>
<tr>
<td>20-25mmHg</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>25-30mm Hg</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>&gt;30mm Hg</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

**Table 5:** shows IOP changes (Among 100 patients in 34% around 2mmHg rise of IOP noted)

![IOP Changes Chart]

**Discussion**

Glycosaminoglycans are the most abundant heteropolysaccharide in the human eye. They are key constituent of the extracellular matrix and act as a filler substance between cells and fibers in the tissues. Normal aqueous out flow is affected by GAG content which acts like a gel and are important contributor for outflow resistance.

In our prospective study which was conducted in GIMSR for a period of 1 year from March 2017 to March 2018 around 100 patients were diagnosed to have Osteoarthritis and were put on glucosamine sulphate 750 mg thrice a day. IOP was measured in these 100 patients in about 5 consecutive visits 3 months apart each and IOP rise was checked. In initial visits there was not any IOP changes but around 6 months duration 34% of patients have shown 2 mm Hg IOP rise where as 66% of patients did not show any IOP changes. Among 34% of patients commonest age group to show changes in IOP was 40 to 60 years and younger generation did not show much changes. This results corresponds to study conducted by Murphy et al stating that younger generation were not much affected.

In our study there was not much rise of IOP but in the study of Murphy et al they have stated that there was significant rise in IOP. Our results of 2 mm Hg in both eyes rise of IOP corresponds to
clinical trial of H. Esfandiari et al and Larid Harrison study.
Commonest age group affected was around 40 to 60 yrs in our study but study conducted by Larid Harrison et al was >60 yrs. Binninger et al showed that exogenous GAG stimulate cultured human trabecular meshwork cells to produce more GAG as positive feedback mechanism.

**Conclusion**
Out of total number of 20000 patients attended Orthopaedics department from March 2017 to March 2018, 5000 patients complained of knee problem. Among them 100 patients were selected for the study. Patients with previous history of glaucoma, previous surgeries, fundus changes, not willing for regular follow up and corneal abnormalities were excluded from the study.
Measurement of IOP was done in all 100 patients before usage of Glucosamine sulphate and patients were instructed to come for regular follow ups 3 monthly.

- In our study major proportion of patients were females constituting 78% compared to males who were only 22%.
- Commonest age group affected both in males and females was 40-60 years.
- Normal range of 10 to 20 mm Hg IOP was seen in almost 90% of the patients.
- After administration of drug for a period of 3 months not much IOP change was noticed.
- After 6 months 34% of patients have shown 2 mm Hg increase in IOP but were within the normal range.
- Thus glucosamine sulphate can be used in Osteoarthritis with regular monitoring of IOP and considered to be relatively safe.

**References**